Drug Trial Radar · NCT03905148
Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
91
Actual
Start
May 1, 2019
Primary completion
Oct 9, 2024
Study completion Oct 23, 2025
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- Collaborators
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Conditions
- Solid Tumor, Adult
Interventions
LifirafenibDrug
RAF Dimer Inhibitor
mirdametinibDrug
MEK Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events and Serious Adverse EventsTime frame: Approximately 2 years from date of the participants enrollment
- The incidence of DLT events and treatment-emergent AEs (TEAEs)Time frame: Approximately 2 years from date of the participants enrollment
- Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor typesTime frame: Approximately 2 years from date of the participants enrollment
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Santa Monica, California
MD Anderson
Houston, Texas
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
The Prince of Wales Private Hospital - Specialist Medical Randwick
Randwick, New South Wales, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.